Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(20%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
1
20%
Ph phase_4
2
40%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(3)
Other(1)

Detailed Status

Completed3
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)
N/A1 (20.0%)

Trials by Status

completed360%
recruiting120%
unknown120%

Recent Activity

1 active trials
Showing 5 of 5
recruitingnot_applicable

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

NCT04970836
unknownphase_4

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

NCT06209398
completedphase_2

Protectivity and Safety Following Recombinant Hepatitis B Vaccine

NCT03919578
completedphase_3

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

NCT01453348
completedphase_4

Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

NCT01758185

Clinical Trials (5)

Showing 5 of 5 trials
NCT04970836Not Applicable

The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort

Recruiting
NCT06209398Phase 4

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

Unknown
NCT03919578Phase 2

Protectivity and Safety Following Recombinant Hepatitis B Vaccine

Completed
NCT01453348Phase 3

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Completed
NCT01758185Phase 4

Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5